Abstract
The Comprehensive Support Project for Oncology Research in Breast Cancer (CSPOR-BC) was initiated in 2000 as part of the investigation project of the Stress Science Research Institute, which was founded by the Public Health Research Foundation. The main objective of CSPOR-BC is to comprehensively support investigator-initiated clinical trials, research related to health-related quality of life (HR-QOL), and epidemiological research for breast cancer. After its initiation, 6 randomized controlled trials (RCTs) on adjuvant therapy for breast cancer and 2 RCTs on metastatic breast cancer have been conducted. To date, patient recruitment has been completed in 3 trials on adjuvant therapy and 1 trial on metastatic breast cancer. In addition to the assessment of efficacy and quality of life, treatment-related side effects have been evaluated. Large cohort studies have been accompanied by some RCTs to evaluate the effect of lifestyle, use of complementary and alternative medicine, sociopsychological factors, and supportive therapies on prognoses of patients with primary breast cancer. These subanalyses are unique to clinical trials conducted by CSPOR-BC. In this report, the current status and future perspectives of CSPOR-BC are described.
Similar content being viewed by others
References
Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19:1–3.
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17:1483–91.
Shiroiwa T, Fukuda T, Shimozuma K, Kuranami M, Suemasu K, Ohashi Y, et al. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial. Value Health. 2011;14:746–51.
Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010;121:379–87.
Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, et al. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03. Breast Cancer Res Treat. 2011;127:143–52.
van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321–31.
Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol. 2011;22:1777–82.
Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, et al. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology. 2010;79:376–81.
Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, et al. (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat (in press)
Iwata H. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. Breast Cancer. 2011;18:92–7.
Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol. 2011;41:709–12.
Mukai H, Takashima T, Hozumi Y, Watanabe T, Murakami S, Masuda N, et al. Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). Jpn J Clin Oncol. 2010;40:811–4.
Acknowledgments
We are indebted to the women who participated in the clinical trials conducted by CSPOR-BC, and to the doctors, clinical research coordinators, and data managers of our group. The authors thank Enago (http://www.enago.jp) for English language review.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Aihara, T., Mukai, H. The current status and future perspectives of CSPOR-BC. Breast Cancer 20, 287–290 (2013). https://doi.org/10.1007/s12282-012-0386-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-012-0386-6